About Afimmune

Afimmune, headquartered in Dublin, Ireland, is a drug discovery and development company working on new medicines to improve the quality of life for people with rare and inflammatory diseases. Afimmune has assets in various stages of clinical and pre-clinical development. Afimmune pipeline

Latest News

September 19, 2024

Epeleuton for Sickle Cell Disease receives key US patent grant

Dublin, Ireland, 18th September 2024 – Afimmune, a clinical stage drug discovery and development company, today announced that the U.S. Patent and Trademark Office has issued […]

Publications and Conferences

May 13, 2022

EPELEUTON, A NOVEL SYNTHETIC SECOND GENERATION W-3 FATTY ACID, PROTECTS HUMANIZED SICKLE CELL MICE AGAINST HYPOXIA/REOXYGENATION ORGAN DAMAGE

Presentation during EHA2022: All (e)Poster presentations will be made available as of Friday, June 10, 2022 (09:00 CEST) and will be accessible for on-demand viewing until […]

Join our mailing list

Contact us

t: +353 1 2946380 e: [email protected]